Étiquette : psilocybine

Towards mapping neuro-behavioral heterogeneity of psychedelic neurobiology in humans, Flora Moujaes et al., 2023

Towards mapping neuro-behavioral heterogeneity of psychedelic neurobiology in humans Flora Moujaes, Katrin H. Preller, Jie Lisa Ji, John D. Murray, Lucie Berkovitch, Franz X. Vollenweider, Alan Anticevic Biological Psychiatry, 2023 doi : 10.1016/j.biopsych.2022.10.021 ABSTRACT Precision psychiatry aims to identify markers of inter-individual variability that allow predicting the right treatment for each patient. However, bridging the gap between molecular-level manipulations and neural systems-level functional alterations remains an unsolved problem in psychiatry. After decades of low success rates in pharmaceutical R&D for psychiatric drugs, multiple studies now point to the potential of psychedelics as a promising fast-acting and long-lasting treatment for some psychiatric symptoms. Yet, given the highly [...]

Lire la suite

The Rapid Rise in Investment in Psychedelics— Cart Before the Horse, Joshua PHELPS et al., 2022

The Rapid Rise in Investment in Psychedelics— Cart Before the Horse Joshua PHELPS, Ravi N. SHAH, Jeffrey A. LIEBERMAN, JAMA Psychiatry, 2022, 79, (3), 189-190. Doi : 10.1001/jamapsychiatry.2021.3972   Anticipating a renaissance, many psychedelic medicine companies have conducted initial public offerings, where in private companies first issue news hares of stock for sale to the public, making the companies publicly traded entities.1 As of this writing, there are more than 50 publicly traded companies related to the development or administration of psychedelic like drugs in the US, with at least 3 valued at more than $1 billion. The market for psychedelic substances is projected to [...]

Lire la suite

Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects, Friederike Holze et al., 2022

Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects Friederike Holze, Laura Ley, Felix Müller, Anna M. Becker, Isabelle Straumann, Patrick Vizeli, Sebastian Silva Kuehne, Marc A. Roder, Urs Duthaler, Karolina E. Kolaczynska, Nimmy Varghese, Anne Eckert and Matthias E. Liechti Neuropsychopharmacology, 2022, 1-8. Doi : 10.1038/s41386-022-01297-2 Growing interest has been seen in using lysergic acid diethylamide (LSD) and psilocybin in psychiatric research and therapy. However, no modern studies have evaluated differences in subjective and autonomic effects of LSD and psilocybin or their similarities and dose equivalence. We used a double blind, randomized, placebo-controlled, [...]

Lire la suite

Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer, Stephen Ross et al., 2021

Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer Stephen Ross, Gabrielle Agin-Liebes, Sharon Lo, Richard J. Zeifman, Leila Ghazal, Julia Benville, Silvia Franco Corso, Christian Bjerre Real, Jeffrey Guss, Anthony Bossis, and Sarah E. Mennenga ACS Pharmacology & Translational Science, 2021, 4, 553−562. doi : 10.1021/acsptsci.1c00020   ABSTRACT: People with advanced cancer are at heightened risk of desire for hastened death (DHD), suicidal ideation (SI), and completed suicide. Loss of Meaning (LoM), a component of demoralization, can be elevated by a cancer diagnosis and predicts DHD and SI in this population. We completed [...]

Lire la suite

Efficacy and safety of psilocybin-assisted treatment for major depressive disorder : Prospective 12-month follow-up, Natalie Gukasyan et al., 2022

Efficacy and safety of psilocybin-assisted treatment for major depressive disorder : Prospective 12-month follow-up Natalie Gukasyan, Alan K Davis, Frederick S Barrett, Mary P Cosimano, Nathan D Sepeda, Matthew W Johnson and Roland R Griffiths Journal of Psychopharmacology, 2022, Vol. 36(2) 151–158. Doi : 10.1177/02698811211073759   Abstract Background : Preliminary data suggest that psilocybin-assisted treatment produces substantial and rapid antidepressant effects in patients with major depressive disorder (MDD), but little is known about long-term outcomes. Aims : This study sought to examine the efficacy and safety of psilocybin through 12 months in participants with moderate to severe MDD who received psilocybin. Methods : This randomized, waiting-list controlled study [...]

Lire la suite

Psychedelic science in post-COVID-19 psychiatry, J. R. Kelly et al., 2020

Psychedelic science in post-COVID-19 psychiatry J. R. Kelly, M. T. Crockett, L. Alexander, M. Haran, A. Baker, L. Burke, C. Brennan and V. O’Keane Irish Journal of Psychological Medicine, 2020, 1-6. doi:10.1017/ipm.2020.94   The medium- to long-term consequences of COVID-19 are not yet known, though an increase in mental health problems are pre- dicted. Multidisciplinary strategies across socio-economic and psychological levels may be needed to mitigate the mental health burden of COVID-19. Preliminary evidence from the rapidly progressing field of psychedelic science shows that psilocybin therapy offers a promising transdiagnostic treatment strategy for a range of disorders with restricted and maladaptive habitual patterns of cognition [...]

Lire la suite

Effectiveness of Psilocybin on Depression : A Qualitative Study, Redhwan Ahmed Al-Naggar et al., 2021

Effectiveness of Psilocybin on Depression : A Qualitative Study Redhwan Ahmed Al-Naggar, Hisham Alshaikhli, Gwen Erlam Electronic Journal of General Medicine, 2021, 18, (3), em296. doi : 10.29333/ejgm/10862   ABSTRACT Introduction : Psilocybin mushroom use is well documented in spiritual and religious ceremonies globally. This drug is now the most popular in Europe and the USA. Objective : The objective of this study is to explore the experiences and effects of psilocybin on patients with depression and anxiety. Method : A qualitative study was conducted interviewing ten participants currently taking psilocybin while experiencing depression and/or anxiety. Ethical approval was obtained from the University ethics committee. Participants were recruited [...]

Lire la suite

Psychedelic-Assisted Group Therapy : A Systematic Review, Alexander Trope et al., 2019

Psychedelic-Assisted Group Therapy : A Systematic Review Alexander Trope, Brian T. Anderson, Andrew R. Hooker, Giancarlo Glick, Christopher Stauffer, Joshua D. Woolley Journal of Psychoactive Drugs, 2019, 51, (2) 174–188. doi : 10.1080/02791072.2019.1593559 Abstract Contemporary research with classic psychedelic drugs (e.g. lysergic acid diethylamide (LSD) and psilocybin) is indebted to the 20th century researchers and clinicians who generated valuable clinical knowledge of these substances through experimentation. Several recent reviews that highlight the contributions of this early literature have focused on psychedelic-assisted individual psychotherapy modalities. None have attempted to systematically identify and compile experimental studies of psychedelic-assisted group therapy. In therapeutic settings, psychedelics were often used [...]

Lire la suite

On the Relationship between Classic Psychedelics and Suicidality : A Systematic Review, Richard J. Zeifman et al., 2021

On the Relationship between Classic Psychedelics and Suicidality : A Systematic Review Richard J. Zeifman, Nikhita Singhal, Leah Breslow, & Cory R. Weissman ACS Pharmacology & Translational Science, 2021, 4, (2), 436-451 Doi : 10.1021/acsptsci.1c00024 Abstract Use of classic psychedelics (e.g., psilocybin, ayahuasca, lysergic acid diethylamide) is increasing and psychedelic therapy is receiving growing attention as a novel mental health intervention. Suicidality remains a potential safety concern associated with classic psychedelics and is, concurrently, a mental health concern that psychedelic therapy may show promise in targeting. Accordingly, further understanding of the relationship between classic psychedelics and suicidality is needed. Therefore, we conducted a systematic review [...]

Lire la suite